Compounds > tris(1,3-dichloro-2-propyl)phosphate
Page last updated: 2024-12-06

tris(1,3-dichloro-2-propyl)phosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID26177
CHEMBL ID3182032
CHEBI ID143729
SCHEMBL ID333198
MeSH IDM0067025

Synonyms (70)

Synonym
tris[2-chloro-1-(chloromethyl)ethyl] phosphate
13674-87-8
tris-(1,3-dichloro-2-propyl)phosphate
tris(1,3-dichloroisopropyl)phosphate
fyrol fr 2
inchi=1/c9h15cl6o4p/c10-1-7(2-11)17-20(16,18-8(3-12)4-13)19-9(5-14)6-15/h7-9h,1-6h
crp (fireproofing agent)
tris(1-chloromethyl-2-chloroethyl)phosphate
tris(2-chloro-1-(chloromethyl)ethyl) phosphate
tri(beta,beta'-dichloroisopropyl)phosphate
pf 38/3
einecs 237-159-2
fyrol fr-2
ccris 6284
tdcpp
tris(1,3-dichloro-2-propyl)phosphate
emulsion 212
1,3-dichloro-2-propanol phosphate (3:1)
fosforan troj-(1,3-dwuchloroizopropylowy) [polish]
pf 38
brn 1715458
hsdb 4364
tris(2-chloro-1-(chloromethyl)ethyl)phosphate
CRP ,
2-propanol, 1,3-dichloro-, phosphate (3:1)
tris(1,3-dichloro-2-propyl) phosphate
phosphoric acid tris(1,3-dichloro-2-propyl) ester
FT-0654115
P0269
tris(1,3-dichloropropan-2-yl) phosphate
CHEBI:143729
A807122
tris(1,3-dichloro-2-propyl) phosphate;tris(1,3-dichloro-2-propyl)phosphate
NCGC00247923-01
NCGC00247923-02
3-01-00-01473 (beilstein handbook reference)
b1prv4g0t0 ,
unii-b1prv4g0t0
fosforan troj-(1,3-dwuchloroizopropylowy)
ec 237-159-2
2-propanol, 1,3-dichloro-, 2,2',2''-phosphate
tox21_300194
NCGC00254047-01
NCGC00259715-01
dtxsid9026261 ,
tox21_202166
cas-13674-87-8
dtxcid206261
tdcipp
S12389
AKOS015856734
tris(1,3-dichloro-2-propyl)phosphate [hsdb]
tdcpp [mi]
SCHEMBL333198
phosphoric acid tris(1,3-dichloro-2-propyl)ester
tri(.beta.,.beta.'-dichloroisopropyl)phosphate
tris[2-chloro-1-(chloromethyl)ethyl] phosphate #
ASLWPAWFJZFCKF-UHFFFAOYSA-N
HY-108712
CS-8011
CHEMBL3182032
tris(1,3-dichloro-2-propyl) phosphate, 95%
mfcd00083121
tdcpp, analytical standard
J-006902
tris(1.3-dichloro-2-propyl) phosphate
phosphoric acid tris-(2-chloro-1-chloromethyl-ethyl) ester
Q2454085
tris-(1,3-dichloroisopropyl) phosphate standard 50 microg/ml in acetonitrile
fyrol fr 2,tcpp

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" TDCPP was toxic to hepatocytes (LC₅₀ = 60."( Effects of tris(1,3-dichloro-2-propyl) phosphate and tris(1-chloropropyl) phosphate on cytotoxicity and mRNA expression in primary cultures of avian hepatocytes and neuronal cells.
Chiu, S; Crump, D; Kennedy, SW, 2012)		0.38
"Tris(1,3-dichloro-2-propyl) phosphate (TDCIPP) has been frequently detected in environmental media and has adverse health effect on wildlife and humans."( Acute Exposure to Tris(1,3-dichloro-2-propyl) Phosphate (TDCIPP) Causes Hepatic Inflammation and Leads to Hepatotoxicity in Zebrafish.
Agrawal, I; Giesy, JP; Gong, Z; Letcher, RJ; Li, G; Li, J; Liu, C; Su, G; Wang, J; Yu, L, 2016)		0.43
" Due to the hazardous effects of many of these chemicals, manufacturers are developing next generation potential less toxic alternatives."( Acute mixture toxicity of halogenated chemicals and their next generation counterparts on zebrafish embryos.
Abdel-Moneim, A; Godfrey, A; Sepúlveda, MS, 2017)		0.46
" Developmental toxicity is a major concern of OPFRs' adverse health effects."( Exposure to tris(1,3-dichloro-2-propyl) phosphate (TDCPP) induces vascular toxicity through Nrf2-VEGF pathway in zebrafish and human umbilical vein endothelial cells.
Kang, J; Qiu, J; Shi, X; Wei, Y; Xing, X; Zhong, X, 2019)		0.51
"As the application and environmental release of tris(1,3-dichloro-2-propyl) phosphate (TDCIPP) are being increased rapidly, serious concerns have been raised regarding its adverse effects on human health."( Sub-chronic exposure to Tris(1,3-dichloro-2-propyl) phosphate induces sex-dependent hepatotoxicity in rats.
Hu, X; Li, X; Wang, S, 2019)		0.51
" The ubiquitous distribution and persistence of TDCPP in aquatic environment have led to concerns over its possible toxic effects on aquatic organism."( Toxic effect and mechanism of tris (1,3-dichloro-2-propyl)phosphate (TDCPP) on the marine alga Phaeodactylum tricornutum.
Jian, X; Liu, Q; Ma, W; Tang, X; Wang, Y; Yang, Y; Zhang, X, 2020)		0.56
"Humans are exposed to many xenobiotics simultaneously, but little is known about the toxic effects based on chemical-chemical interactions."( Impact of Mixture Effects between Emerging Organic Contaminants on Cytotoxicity: A Systems Biological Understanding of Synergism between Tris(1,3-dichloro-2-propyl)phosphate and Triphenyl Phosphate.
Chen, D; Cheng, HS; Fang, M; Jia, S; Koh, D; Liu, M; Peng, B; Tan, NS; Wang, Y; Warth, B; Zhang, Y, 2020)		0.76
" The DEPs associated with toxic effects of TDCIPP were then screened by use of Gene Ontology and the Kyoto Encyclopedia of Genes and Genomes for enrichment analysis."( Proteomic analysis using isobaric tags for relative and absolute quantification technology reveals mechanisms of toxic effects of tris (1,3-dichloro-2-propyl) phosphate on RAW264.7 macrophage cells.
Giesy, JP; Wang, P; Wang, R; Wei, S; Zhang, S; Zhang, W, 2022)		0.72

Bioavailability

ExcerptReferenceRelevance
" Microplastics (plastic particles < 5 mm) and nanoplastics (plastic particles < 100 nm) can interact with organic pollutants already present in the aquatic environment, potentially acting as carriers for pollutants entering organisms and thus influencing the bioavailability and toxicity of those pollutants."( Parental transfer of nanopolystyrene-enhanced tris(1,3-dichloro-2-propyl) phosphate induces transgenerational thyroid disruption in zebrafish.
Duan, X; Liu, Z; Ren, X; Zhao, X, 2021)		0.62

Dosage Studied

ExcerptRelevanceReference
" Dermal uptake and percutaneous penetration of the OPEs were studied in a Franz diffusion cell system using human skin dosed with a mixture of OPEs in an ethanol:toluene (4:1) solution."( Dermal uptake and percutaneous penetration of organophosphate esters in a human skin ex vivo model.
Clausen, PA; Frederiksen, M; Jensen, NM; Knudsen, LE; Nielsen, F; Nielsen, JB; Stapleton, HM; Sørensen, JA; Sørensen, LS; Vorkamp, K; Webster, TF, 2018)		0.48
" Exposure to TDCPP resulted in a dose-response decrease of micoalgal biomass."( Metabolomics reveals that tris(1,3-dichloro-2-propyl)phosphate (TDCPP) causes disruption of membrane lipids in microalga Scenedesmus obliquus.
Huang, X; Laserna, AKC; Li, SFY; Wang, L, 2020)		0.86
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
trialkyl phosphate
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (22)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency27.42530.006038.004119,952.5996AID1159521; AID1159523
GLI family zinc finger 3Homo sapiens (human)Potency1.44220.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency41.47750.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743036; AID743042; AID743054; AID743063
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency61.36180.000657.913322,387.1992AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency40.68510.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency7.26000.000417.946075.1148AID1346795
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency13.61810.000214.376460.0339AID720691; AID720692; AID720719
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency40.83400.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency16.42010.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency50.93940.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency49.00070.375827.485161.6524AID743217; AID743220
pregnane X nuclear receptorHomo sapiens (human)Potency20.15730.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency44.16180.000229.305416,493.5996AID1259244; AID1259248; AID743069; AID743075; AID743078; AID743079
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency43.64120.001019.414170.9645AID743191
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency61.39770.001723.839378.1014AID743083
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency7.11440.057821.109761.2679AID1159526; AID1159528
Histone H2A.xCricetulus griseus (Chinese hamster)Potency11.24540.039147.5451146.8240AID1224845
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency64.68580.000323.4451159.6830AID743065; AID743067
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency61.36180.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency61.36180.001551.739315,848.9004AID1259244
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency68.24100.011917.942071.5630AID651632
Ataxin-2Homo sapiens (human)Potency68.24100.011912.222168.7989AID651632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (18)

Processvia Protein(s)Taxonomy
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Research

Studies (87)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (10.34)18.7374
1990's0 (0.00)18.2507
2000's3 (3.45)29.6817
2010's59 (67.82)24.3611
2020's16 (18.39)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.62

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.62 (24.57)
Research Supply Index4.50 (2.92)
Research Growth Index5.85 (4.65)
Search Engine Demand Index38.54 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (30.62)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (2.25%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other87 (97.75%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
cytosine
[no description available]		7.2110aminopyrimidine;
pyrimidine nucleobase;
pyrimidone		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
chlorpyrifos
Chlorpyrifos: An organothiophosphate cholinesterase inhibitor that is used as an insecticide and as an acaricide.. chlorpyrifos : An organic thiophosphate that is O,O-diethyl hydrogen phosphorothioate in which the hydrogen of the hydroxy group has been replaced by a 3,5,6-trichloropyridin-2-yl group.		2.1310chloropyridine;
organic thiophosphate		acaricide;
agrochemical;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
environmental contaminant;
insecticide;
xenobiotic
thyroxine
Thyroxine: The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.. thyroxine : An iodothyronine compound having iodo substituents at the 3-, 3'-, 5- and 5'-positions.		2.51202-halophenol;
iodophenol;
L-phenylalanine derivative;
non-proteinogenic L-alpha-amino acid;
thyroxine zwitterion;
thyroxine		antithyroid drug;
human metabolite;
mouse metabolite;
thyroid hormone
triiodothyronine
Triiodothyronine: A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.. 3,3',5-triiodo-L-thyronine : An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism.		2.58202-halophenol;
amino acid zwitterion;
iodophenol;
iodothyronine		human metabolite;
mouse metabolite;
thyroid hormone
phencyclidine
Phencyclidine: A hallucinogen formerly used as a veterinary anesthetic, and briefly as a general anesthetic for humans. Phencyclidine is similar to KETAMINE in structure and in many of its effects. Like ketamine, it can produce a dissociative state. It exerts its pharmacological action through inhibition of NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE). As a drug of abuse, it is known as PCP and Angel Dust.. phencyclidine : A member of the class of piperidines that is piperidine in which the nitrogen is substituted with a 1-phenylcyclohexyl group. Formerly used as an anaesthetic agent, it exhibits both hallucinogenic and neurotoxic effects.		4.9680benzenes;
piperidines		anaesthetic;
neurotoxin;
NMDA receptor antagonist;
psychotropic drug
triethyl phosphate
triethyl phosphate: structure. triethyl phosphate : A trialkyl phosphate that is the triethy ester derivative of phosphoric acid.		2.1310trialkyl phosphate
tris(2-butoxyethyl) phosphate
tris(2-butoxyethyl) phosphate: inhibitor of drug-protein binding; present in stoppers of blood sample 'vacutainers'. tris(2-butoxyethyl) phosphate : A trialkyl phosphate in which the alkyl group specified is 2-butoxyethyl.		3.0440trialkyl phosphateenvironmental contaminant;
flame retardant
tetrabromobisphenol a
tetrabromobisphenol A: a brominated flame retardant. 3,3',5,5'-tetrabromobisphenol A : A bromobisphenol that is 4,4'-methanediyldiphenol in which the methylene hydrogens are replaced by two methyl groups and the phenyl rings are substituted by bromo groups at positions 2, 2', 6 and 6'. It is a brominated flame retardant.		3.0540brominated flame retardant;
bromobisphenol
triphenyl phosphite
[no description available]		2.9710
acrolein
[no description available]		1.9510enalherbicide;
human xenobiotic metabolite;
toxin
triphenyl phosphate
triphenyl phosphate: structure. triphenyl phosphate : An aryl phosphate resulting from the formal condensation of phosphoric acid with 3 mol eq. of phenol.		9.82110aryl phosphateflame retardant;
plasticiser
tris(chloroethyl)phosphate
tris(chloroethyl)phosphate: has gonadotoxic effects. tris(2-chloroethyl) phosphate : A trialkyl phosphate that is the tris(2-chloroethyl) ester of phosphoric acid.		2.4110organochlorine compound;
trialkyl phosphate
perfluorooctanoic acid
perfluorooctanoic acid: RN given refers to parent cpd. perfluorooctanoic acid : A fluoroalkanoic acid that is perfluorinated octanoic acid.		2.5520fluoroalkanoic acidcarcinogenic agent;
endocrine disruptor;
environmental contaminant;
surfactant;
xenobiotic
perfluorobutyric acid
perfluorobutyric acid: ion pairing reagent; RN given refers to parent cpd. perfluorobutyric acid : A monocarboxylic acid that is perfluorinated butyric acid.		2.1510fluoroalkanoic acidchromatographic reagent;
environmental contaminant;
xenobiotic
decabromobiphenyl ether
decabromobiphenyl ether: a flame retardant. decabromodiphenyl ether : A polybromodiphenyl ether that is diphenyl ether in which all of the hydrogens have been replaced by bromines.		210polybromodiphenyl etherneurotoxin
chlorine
Chlorine: An element with atomic symbol Cl, atomic number 17, and atomic weight 35, and member of the halogen family.		2.1710diatomic chlorine;
gas molecular entity		bleaching agent
dechlorane plus
dechlorane plus: a flame retardant; structure in first source		2.1710
tri-(2-chloroisopropyl)phosphate
[no description available]		2.8230trialkyl phosphate
tris(2,3-dibromopropyl)phosphate
tris(2,3-dibromopropyl)phosphate: flame retardant		4.88110trialkyl phosphate
2,2',4,4'-tetrabromodiphenyl ether
[no description available]		2.5520aromatic ether;
organobromine compound
phosphites
Phosphites: Inorganic salts or organic esters of phosphorous acid that contain the (3-)PO3 radical. (From Grant & Hackh's Chemical Dictionary, 5th ed). phosphite(3-) : A trivalent inorganic anion obtained by removal of all three protons from phosphorous acid.		2.9710phosphite ion;
trivalent inorganic anion
caprylates
Caprylates: Derivatives of caprylic acid. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain a carboxy terminated eight carbon aliphatic structure.. octanoate : A straight-chain saturated fatty acid anion that is the conjugate base of octanoic acid (caprylic acid); believed to block adipogenesis.		2.5520fatty acid anion 8:0;
straight-chain saturated fatty acid anion		human metabolite;
Saccharomyces cerevisiae metabolite
tris(2-carboxyethyl)phosphine
tris(2-carboxyethyl)phosphine: water-soluble reagent which irreversibly reduces disulfides to thiols at room temperature & is active below neutral pH; used for quantitation of iodine and iodate. TCEP : A tertiary phosphine in which phosphane is substituted with three 2-carboxyethyl groups. It is a commonly used reducing agent.		3.3760phosphine derivative;
tricarboxylic acid		reducing agent
organophosphonates
hydrogenphosphite : A divalent inorganic anion resulting from the removal of a proton from two of the hydroxy groups of phosphorous acid.		310divalent inorganic anion;
phosphite ion
nadp
[no description available]		1.9610
ovalbumin
Ovalbumin: An albumin obtained from the white of eggs. It is a member of the serpin superfamily.		2.3110
11-ketotestosterone
11-ketotestosterone: RN given refers to cpd without isomeric designation. 11-oxotestosterone : A 3-oxo Delta(4)-steroid that is testosterone carrying an additional oxo substituent at position 11.		2.111011-oxo steroid;
17beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
androstanoid		androgen;
human metabolite;
marine xenobiotic metabolite
4-hydroxy-2-nonenal
4-hydroxy-2-nonenal: cytotoxic product from peroxidation of liver microsomal lipids; RN given refers to cpd without isomeric designation. 4-hydroxynon-2-enal : An enal consisting of non-2-ene having an oxo group at the 1-position and a hydroxy group at the 4-position.. 4-hydroxynonenal : A monounsaturated fatty aldehyde that is nonanal that has undergone dehydrogenation to introduce a double bond at any position in the aliphatic chain and in which a hydrogen at position 4 has been replaced by a hydroxy group.		2.21104-hydroxynon-2-enal;
4-hydroxynonenal
phosphorus
Phosphorus: A non-metal element that has the atomic symbol P, atomic number 15, and atomic weight 31. It is an essential element that takes part in a broad variety of biochemical reactions.		2.1710monoatomic phosphorus;
nonmetal atom;
pnictogen		macronutrient
diphenyl phosphite
diphenyl phosphite: a coupling agent for making sterically hindered peptide analogs; structure in first source		310
2-ethylhexyl 2,3,4,5-tetrabromobenzoate
2-ethylhexyl 2,3,4,5-tetrabromobenzoate: structure in first source		2.1510
tetracarboxyphenylporphine
[no description available]		2.4620
phenanthrenes
Phenanthrenes: POLYCYCLIC AROMATIC HYDROCARBONS composed of three fused BENZENE rings.. phenanthrenes : Any benzenoid aromatic compound that consists of a phenanthrene skeleton and its substituted derivatives thereof.		2.1510
ConditionIndicatedRelationship StrengthStudiesTrials
Interstitial Cell Tumor
[description not available]		02.4110
Cardiometabolic Syndrome
A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components not only include metabolic dysfunctions of METABOLIC SYNDROME but also HYPERTENSION, and ABDOMINAL OBESITY.		03.5240
Diabetes Mellitus, Adult-Onset
[description not available]		03.5240
Insulin Sensitivity
[description not available]		03.5240
Diabetes Mellitus, Type 2
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.		03.5240
Insulin Resistance
Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.		03.5240
Metabolic Syndrome
A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.		03.5240
Acute Liver Injury, Drug-Induced
[description not available]		02.5720
Chemical and Drug Induced Liver Injury
A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.		02.5720
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		02.4220
Encephalopathy, Toxic
[description not available]		02.8530
Innate Inflammatory Response
[description not available]		02.5820
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.5820
Asthma, Bronchial
[description not available]		02.3110
Asthma
A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).		07.3110
Neuroblastoma
A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)		02.8430
Aging
The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.		02.2110
Cirrhosis
[description not available]		02.110
Fibrosis
Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.		02.110
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		02.420
Abnormalities, Autosome
[description not available]		01.9510
Germinoblastoma
[description not available]		01.9510
Lymphoma
A general term for various neoplastic diseases of the lymphoid tissue.		01.9510
Kidney Diseases
Pathological processes of the KIDNEY or its component tissues.		01.9610